emailContact Us    ASIP MEMBER ACCESS    Become a Supporter    News    Job Seekers/Employers    facebookGoogle+twitterinstagramlinkedinflickrYoutube



Award Application Deadline: 
(The Awards Application Deadline was November 17, 2016)

Late-Breaking Abstract Submission Deadline:
February 8, 2017

Early Registration Deadline:
February 23, 2017

Hotel Reservations Deadline:
March 31, 2017






Breast Cancer Workshop: Ductal Carcinoma In Situ - Discerning Aggressive Versus Benign Disease Using Molecular Features

Go back to the meeting program

Saturday, April 22, 2017
8:30 AM - 11:30 AM
Chaired by William B. Coleman, PhD
Sponsored by the ASIP Breast Cancer and Tumor Microenvironment & Metastasis Scientific Interest Groups

8:30 AM - 9:15 AM
Breast Ductal Carcinoma In Situ - Precursor to Invasive Breast Cancer
William B. Coleman PhD
University of North Carolina Chapel Hill School of Medicine - Department of Pathology & Laboratory Medicine

9:15 AM - 10:00 AM
Gene Expression Patterns in Breast DCIS Predict Aggressiveness of Disease
Lawrence J. Solin MD
Albert Einstein Medical Center - Department of Radiation Oncology
Ductal carcinoma in situ (DCIS; intraductal carcinoma) is a non-obligate precursor of invasive carcinoma of the breast. Prospective randomized trials have demonstrated that adding radiation treatment and tamoxifen after lumpectomy (surgical excision) significantly improve the risk of recurrence, but not survival. Given the need to develop molecular tools in the setting of selecting local treatment for DCIS, the 12-gene Oncotype DX DCIS Score was developed and validated to predict risks of local recurrence and the subset of invasive local recurrence after lumpectomy alone (without radiation treatment), independent of tamoxifen use. The DCIS Score includes 12 genes, which are a subset of the 21 genes in the Onctotype DX Recurrence Score (for invasive carcinoma). These 12 genes are comprised of five genes in the proliferation group, progesterone receptor, GSTM1, and five reference genes. Using the ECOG-ACRIN E5194 study in which patients were treated with lumpectomy (without radiation treatment), the DCIS Score was associated with the 10-year risks of developing an ipsilateral breast event (IBE; local recurrence) (p = 0.006) and the subset of an invasive IBE (p = 0.003). On multivariable analysis, the DCIS Score, tumor size, and menopausal status were independently statistically significant for local recurrence (all p d 0.02). Analysis of grade did not demonstrate a significant correlation with local recurrence. These results validated the DCIS Score as a predictor of local recurrence and invasive local recurrence, quantified the 10-year risk of local recurrence, and provided independent information beyond conventional clinical and pathologic variables. The 12-gene DCIS Score was independently validated a second time using a population-based cohort from Ontario, Canada. Comparing the data from the ECOG-ACRIN E5914 study and the population-based cohort study from Canada demonstrates remarkably similar results, including local recurrence, the subset of invasive local recurrence, and hazard function. The similar results in these two validation studies support the clinical implementation of the 12-gene DCIS Score in accordance with rigorous scientific principles for tumor biomarker development and validation.

10:00 AM - 10:45 AM
MicroRNA Expression Signatures Predict Aggressiveness of Breast DCIS
Bethany N. Hannafon PhD
University of Oklahoma Health Science Center - Department of Pathology

Abstract: Ductal carcinoma in situ (DCIS) is defined as a proliferation of neoplastic cells within the duct of the mammary gland, that have not invaded into the surrounding stroma. DCIS is considered a precursor to invasive ductal carcinoma (IDC), however, approximately only half of DCIS may progress to IDC, if left untreated. Current research has shown that the genomic and transcriptomic changes observed in IDC are also present in DCIS, indicating that the malignant nature of DCIS is defined prior to progression. However, important questions remain, including the identification of the specific changes required for malignant progression and prognostic indicators of the aggressiveness of DCIS. microRNAs are small (17-21 nucleotides) regulatory RNAs that modulate gene expression by complementary binding to target mRNAs and inducing translational repression and/or mRNA degradation. microRNAs regulate many important normal cellular processes and contribute to the pathogenesis of many diseases, including breast cancer. In the last decade, research has shown that microRNA expression is dysregulated in IDC, and that these changes are already present at the DCIS stage. Therefore, microRNAs may provide the necessary information required to identify a prognostic indicator of DCIS progression. Here, we will review the microRNA signatures identified in DCIS and discuss how they may be utilized to predict the aggressiveness of DCIS.

10:45 AM - 11:30 AM
The Future of Molecular Testing in Breast DCIS
Gregory J. Tsongalis PhD
Dartmouth-Hitchcock Medical Center - Department of Pathology

Go back to the meeting program